Letters
Inhaled insulin: Concerns remain
BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7552.1273-e (Published 25 May 2006) Cite this as: BMJ 2006;332:1273
- Niamh M Martin, specialist registrar (n.martin@imperial.ac.uk),
- Karim Meeran, consultant
- Metabolic Medicine Unit, Hammersmith Hospital, London W12 0HS
- Metabolic Medicine Unit, Hammersmith Hospital, London W12 0HS
EDITOR—Morton-Eggleston and Barrett conclude that the adverse effects of inhaled insulin are not clinically worrisome.1 Insulin is a potent mitogen and growth factor in the lung, leading to concerns that repeated inhaled delivery of insulin results in supraphysiological alveolar insulin deposition which …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.